S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:BGNE

BeiGene Stock Forecast, Price & News

$320.00
-9.73 (-2.95 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$313.26
Now: $320.00
$327.21
50-Day Range
$278.92
MA: $345.42
$382.12
52-Week Range
$118.55
Now: $320.00
$388.97
Volume397,200 shs
Average Volume338,039 shs
Market Capitalization$29.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.
BeiGene logo

Headlines

BeiGene closes - Seeking Alpha
February 26, 2021 |  seekingalpha.com
Can BeiGene Stock Rebound After A 10% Drop?
February 26, 2021 |  forbes.com
Form 8-K Zymeworks Inc. For: Feb 24 - StreetInsider.com
February 25, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
CUSIPN/A
Phone1-345-949-4123
Employees4,600
Year Founded2010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$428.21 million
Book Value$15.87 per share

Profitability

Net Income$-948,630,000.00
Net Margins-569.22%

Miscellaneous

Market Cap$29.27 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.09 out of 5 stars

Medical Sector

936th out of 1,962 stocks

Pharmaceutical Preparations Industry

453rd out of 772 stocks

Analyst Opinion: 1.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$320.00
-9.73 (-2.95 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BeiGene (NASDAQ:BGNE) Frequently Asked Questions

Is BeiGene a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BeiGene stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BGNE, but not buy additional shares or sell existing shares.
View analyst ratings for BeiGene
or view top-rated stocks.

What stocks does MarketBeat like better than BeiGene?

Wall Street analysts have given BeiGene a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BeiGene wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for BeiGene
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings data on Thursday, February, 25th. The company reported ($5.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.23) by $0.97. BeiGene had a negative trailing twelve-month return on equity of 56.81% and a negative net margin of 569.22%.
View BeiGene's earnings history
.

How has BeiGene's stock been impacted by COVID-19 (Coronavirus)?

BeiGene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BGNE shares have increased by 119.6% and is now trading at $320.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BGNE?

7 brokers have issued 1-year price objectives for BeiGene's shares. Their forecasts range from $190.00 to $429.00. On average, they expect BeiGene's share price to reach $308.17 in the next twelve months. This suggests that the stock has a possible downside of 3.7%.
View analysts' price targets for BeiGene
or view top-rated stocks among Wall Street analysts.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, Chairman & CEO (Age 53, Pay $1.58M) (LinkedIn Profile)
  • Dr. Xiaobin Wu Ph.D., GM of China & Pres (Age 58, Pay $1.13M)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Committee & Non-Exec. Director (Age 58, Pay $4M)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 58, Pay $694.61k)
  • Dr. Jane Edna Huang M.D., Chief Medical Officer of Hematology (Age 48, Pay $705.49k)
  • Mr. Daniel Maller, VP of Fin. & Accounting
  • Mr. Craig West CFA, Sr. Director of Investor Relations
  • Mr. Scott Samuels, Sr. VP & Gen. Counsel
  • Ms. Diana Lee Francis, VP and Global Head of Quality & Regulatory Compliance
  • Mr. Luo Lusong, Head of Discovery Biology & Sr. VP

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

Who are some of BeiGene's key competitors?

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology Group (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a variety of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (12.80%), FMR LLC (5.16%), Baillie Gifford & Co. (4.66%), Primecap Management Co. CA (3.69%), BlackRock Inc. (2.84%) and Artal Group S.A. (1.10%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene
.

Which major investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Hsbc Holdings PLC, FMR LLC, Sands Capital Management LLC, Sumitomo Mitsui Trust Holdings Inc., Alliancebernstein L.P., Van ECK Associates Corp, and Northern Trust Corp. Company insiders that have sold BeiGene company stock in the last year include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene
or view top insider-selling stocks.

Which major investors are buying BeiGene stock?

BGNE stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., BlackRock Inc., Canada Pension Plan Investment Board, JPMorgan Chase & Co., Artal Group S.A., Amundi Pioneer Asset Management Inc., Long Corridor Asset Management Ltd, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for BeiGene
or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $320.00.

How much money does BeiGene make?

BeiGene has a market capitalization of $29.27 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 4,600 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

What is BeiGene's official website?

The official website for BeiGene is www.beigene.com.

Where are BeiGene's headquarters?

BeiGene is headquartered at 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.